Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TV-46000 maintenance treatment study in schizophrenia
2018-001619-65Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing TV-46000 with Placebo (2 arms). Primary endpoint: Time to impending relapse. Started Jul 2018; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2018-001619-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001619-65.